NYNurcin Yilmaz

Nurcin Yilmaz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nurcin Yilmaz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pharmacokinetics of meloxicam following intramuscular, subcutaneous, and oral administration in white storks (Ciconia ciconia)

    by Yigit Gunes, Ebuderda Gunay, Nurcin Yilmaz, Emine Irem Deveci, Dilek Ozturk Civelek, Ceren Anlas, Tulay Bakirel, Oya Ustuner, Ali Serhan Coskun, Duygu Sultan Oran, et al.

    Background: Meloxicam (MLX) is a preferential cyclooxygenase-2 inhibitor widely used in avian medicine as an anti-inflammatory agent. Despite marked interspecific variability in avian drug disposition, no pharmacokinetic data are available for MLX in the white stork ( Ciconia ciconia ). This study aimed to characterise and compare the plasma pharmacokinetics of MLX in this species. Methods: Six clinically stable, non-releasable white storks (three of each sex) received a single 1 mg/kg dose of MLX by the IM, SC and PO routes in a randomised three-way crossover design with a 2-week washout period between treatments. Plasma MLX concentrations were quantified up to 24 h using HPLC and analysed using non-compartmental methods. Results: Peak plasma concentrations (C max ) differed significantly among all three routes (IM 11.49 ± 2.34, SC 6.43 ± 1.62, PO 1.53 ± 0.89 µg/mL; p < 0.05) and the median time to peak concentration (tmax) was progressively delayed from IM (0.67 h) through SC (2.00 h) to PO (4.00 h). Systemic exposure did not differ significantly between the IM and SC routes (AUC 0–24 h 80.7 ± 40.2 and 81.1 ± 22.7 µg·h/mL, respectively) and approximately 7-fold greater than after PO administration (11.9 ± 4.8 µg·h/mL; p < 0.05), corresponding to relative bioavailabilities versus IM of 100.4% for SC and 14.8% for PO. Terminal half-life progressively increased from IM (9.81 ± 2.30 h) through SC (15.13 ± 4.41 h) to PO (18.85 ± 2.16 h). Conclusion: SC administration may represent a practical parenteral alternative to IM, whereas PO administration displayed low and variable bioavailability in white storks.

  • Open Access

    Effects of vitamins A and E on eprinomectin transport in Caco-2 cells

    by Y Gunes, Y Gultekin, O Dogan, C Anlas, O Ustuner, N Yilmaz, T Bakirel

  • Systemic Barriers to Antimicrobial Stewardship in Turkiye: Insights from Veterinary Practices

    by Nurçin Yılmaz, Havvagül Sert, Murat Cengiz

    Antimicrobial resistance (AMR) is a critical global health threat, significantly impacting both human and veterinary medicine. In Türkiye, systemic barriers hinder the effective implementation of antimicrobial stewardship (AMS) in veterinary practice, exacerbating the risks associated with inappropriate antimicrobial use. This study investigates the challenges limiting AMS adoption by analysing veterinarians' prescribing behaviours, diagnostic practices, and adherence to evidence-based guidelines. A cross-sectional survey of 163 veterinarians in Istanbul and Bursa revealed a predominant reliance on empirical antimicrobial prescribing, with third-generation cephalosporins and fluoroquinolones among the most frequently used drug classes. Despite widespread awareness of AMR (92.8%), only 11% of veterinarians reported receiving structured AMS training, and 24% did not utilize microbiological diagnostics for guiding therapy, often citing economic constraints and logistical barriers. Additionally, AMS strategies were predominantly reactive, with 64% of respondents favouring retrospective case review over proactive prescribing restrictions. Key barriers to AMS implementation included financial pressures, regulatory gaps, limited diagnostic accessibility, and client-driven demands for antimicrobial therapy. These findings underscore the urgent need for targeted AMS education, improved diagnostic infrastructure, and robust regulatory frameworks to optimize antimicrobial use and curb resistance within Türkiye’s veterinary sector. A multidisciplinary One Health approach is essential to align veterinary practices with global AMR mitigation strategies and ensure sustainable antimicrobial efficacy.